---
title: "Sagimet Biosciences, Inc. Class A (SGMT) Receives a Rating Update from a Top Analyst"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286440726.md"
description: "Debanjana Chatterjee from JonesTrading has reiterated a Buy rating on Sagimet Biosciences, Inc. Class A (SGMT) with a price target of $26.00. Additionally, Wedbush maintained a Buy rating with a $28.00 price target. Chatterjee has an average return of 53.2% and a success rate of 75.97% on recommended stocks, focusing on the Healthcare sector."
datetime: "2026-05-14T15:37:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286440726.md)
  - [en](https://longbridge.com/en/news/286440726.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286440726.md)
---

# Sagimet Biosciences, Inc. Class A (SGMT) Receives a Rating Update from a Top Analyst

In a report released today, Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Sagimet Biosciences, Inc. Class A, with a price target of $26.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Chatterjee covers the Healthcare sector, focusing on stocks such as Spyre Therapeutics, EyePoint Pharmaceuticals, and KalVista Pharmaceuticals. According to TipRanks, Chatterjee has an average return of 53.2% and a 75.97% success rate on recommended stocks.

In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $28.00 price target.

### Related Stocks

- [SGMT.US](https://longbridge.com/en/quote/SGMT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SYRE.US](https://longbridge.com/en/quote/SYRE.US.md)
- [EYPT.US](https://longbridge.com/en/quote/EYPT.US.md)
- [KALV.US](https://longbridge.com/en/quote/KALV.US.md)

## Related News & Research

- [LifeSci Capital Sticks to Their Buy Rating for Tenax Therapeutics (TENX)](https://longbridge.com/en/news/286648286.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Neurothera Labs Announces Adoption of Semi-Annual Reporting](https://longbridge.com/en/news/287119698.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study](https://longbridge.com/en/news/287280796.md)